February 5, 2025
Hot News

Heart cell survival in space sheds light on better treatment strategies on Earth

MyBlueDots01 mins
A team of researchers led by Emory’s Chunhui Xu recently found that heart muscle cells can grow and survive in the microgravity environment of space. The team’s findings, published in Biomaterials, show promise for developing hardier heart cells that could effectively repair damaged hearts in cell therapy—the process of transplanting millions of heart cells to repair damaged hearts—on Earth.
Read More

Asher Bio Announces Clinical Trial Collaboration and Supply Agreement on Etakafusp Alfa (AB248) in Combination with Bispecific T-cell Engager in Patients with Small Cell Lung Cancer

MyBlueDots01 mins
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer and infectious diseases, today announced a clinical trial collaboration and supply agreement with Amgen (NASDAQ:AMGN) to evaluate etakafusp alfa (formerly known as AB248), Asher Bio’s investigational CD8+ T cell targeted interleukin-2 (IL-2) immunotherapy, in combination with IMDELLTRA® (tarlatamab), Amgen’s DLL3-targeting Bispecific T-cell Engage
Read More

Opinion: Utah law allowing minors to revoke medical consent is ‘attacking the foundation of the US health care system’

MyBlueDots01 mins
In Utah, patients who consent to “hormonal transgender treatment” or surgery on “sex characteristics” while they are minors are able to revoke their informed consent if they later regret receiving the care. Under the Health Care Malpractice Act, updated in 2023, minors can recant their consent before age 25 if they develop a “permanent injury” from their treatment, with the argument that their doctor should have anticipated the patient’s health outcome and subsequent regret.
Read More

Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC

MyBlueDots01 mins
SAN FRANCISCO–(BUSINESS WIRE)–Vir Biotechnology, Inc. (Nasdaq: VIR) today is presenting initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, targeting a variety of HER2-expressing solid tumors; and VIR-5500, targeting PSMA in metastatic castration-resistant prostate cancer (mCRPC). Data show encouraging preliminary safety and efficacy profiles with no dose-limiting cytokine release syndrome (CRS), maximum tolerated dose (MTD) not yet reached as dose escalation co
Read More

Medical Properties Trust Comments on Prospect Restructuring

MyBlueDots01 mins
BIRMINGHAM, Ala.–(BUSINESS WIRE)–Medical Properties Trust, Inc. (the “Company” or “MPT”) (NYSE: MPW) today issued the below statement in response to Prospect Medical Group’s (“Prospect”) decision to commence an in-court restructuring process under Chapter 11 of the U.S. Bankruptcy Code. As discussed during MPT’s third quarter 2024 earnings, while Prospect’s California facilities have reported volume growth and improved coverage trends in 2024, its overall liquidity has been adversely impacted
Read More

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

MyBlueDots01 mins
DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that its partner iECURE has reported clinical efficacy and safety data in the first patient dosed with ECUR-506 in the Phase 1/2 OTC-HOPE study. ECUR-506 is iECURE’s in vivo gene insertion program
Read More
Top